Skip to main content
logo
Eli Lilly and Company (LLY)
NYSE: LLY · Real-Time Price · USD
711.68
+1.86 (0.26%)
At close: Aug 22, 2025, 4:00 PM
711.15
-0.53 (-0.07%)
After-hours: Aug 22, 2025, 7:59 PM EDT

Eli Lilly Revenue by Segment

Period EndingMar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017Sep 30, 2017Jun 30, 2017Mar 31, 2017Dec 31, 2016
Diabetes
33.24B29.52B26.16B23.47B20.97B19.67B17.90B16.84B
Diabetes Growth
58.49%50.10%46.17%39.40%37.36%35.97%26.78%22.67%
Oncology
8.89B8.75B8.08B7.60B7.11B6.66B6.43B5.97B
Oncology Growth
24.99%31.45%25.83%27.27%25.46%17.51%18.46%7.85%
Immunology
4.65B4.39B4.21B4.01B3.85B3.80B3.63B3.51B-
Immunology Growth
20.59%15.68%15.98%14.30%14.21%13.54%7.70%0.01%-
Animal Health
-------------------------3.14B3.12B3.08B3.08B3.09B3.13B3.10B3.17B
Animal Health Growth
-------------------------1.84%-0.49%-0.42%-3.01%-2.30%---
Cardiovascular
-------------------------2.25B2.54B2.62B2.74B2.87B3.04B3.15B3.17B
Cardiovascular Growth
--------------------------21.74%-16.63%-17.04%-13.66%-10.98%---
Neuroscience
1.36B1.47B1.44B2.86B2.91B2.88B2.90B1.51B
Neuroscience Growth
-53.34%-48.81%-50.26%89.84%92.66%86.18%77.83%-11.84%
Other
873.90M902.90M968.50M981.80M1.09B1.12B1.22B1.69B
Other Growth
-19.74%-19.54%-20.74%-41.97%-41.83%-68.12%-74.00%-63.16%

Revenue by Geography

Period EndingMar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017Sep 30, 2017Jun 30, 2017Mar 31, 2017Dec 31, 2016
United States
33.17B30.38B27.80B25.35B23.05B21.79B19.99B19.05B
United States Growth
43.91%39.39%39.03%33.10%32.07%19.80%6.88%4.23%
Europe
7.87B6.92B5.81B6.75B6.52B6.17B5.91B4.40B
Europe Growth
20.61%12.08%-1.71%53.44%50.93%43.62%35.21%-0.34%
Rest of World
4.38B4.27B3.95B3.62B3.17B2.95B3.02B2.88B
Rest of World Growth
38.20%44.97%30.64%25.97%14.14%3.30%8.23%0.86%
Japan
1.85B1.81B1.69B1.66B1.65B1.67B1.63B1.73B
Japan Growth
12.34%8.50%4.06%-4.00%-4.35%-4.28%-13.70%-13.48%
China
1.74B1.66B1.61B1.54B1.54B1.54B1.51B1.47B----------------
China Growth
12.43%7.83%6.28%5.01%8.75%5.98%2.35%-4.53%----------------

Operating Expense Breakdown

Period EndingMar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017Sep 30, 2017Jun 30, 2017Mar 31, 2017Dec 31, 2016
Research and Development
11.20B10.99B10.53B10.21B9.85B9.31B8.75B8.14B
Research and Development Growth
13.71%18.01%20.40%25.37%30.21%29.52%22.26%15.30%
Marketing, Selling, and Administrative
9.11B8.59B8.09B7.80B7.61B7.40B7.12B6.93B
Marketing, Selling, and Administrative Growth
19.78%16.08%13.65%12.49%14.69%14.95%11.46%9.12%
Acquired In-Process Research and Development
4.74B3.28B3.71B3.86B3.81B3.80B3.42B504.60M-------
Acquired In-Process Research and Development Growth
24.61%-13.67%8.68%665.46%348.79%318.25%208.95%-58.68%-------
Impairment, Restructuring, and Other
895.60M867.37M561.47M686.37M-355.87M---560.70M492.50M--387.40M-----
Impairment, Restructuring, and Other Growth
151.66%54.69%14.00%77.17%-3.81%---98.20%-33.17%---56.05%-----
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.